Clinical Trials Logo

Clinical Trial Summary

A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib


Clinical Trial Description

The study design is based on a phase I trial in Spanish. A number of 16 patients will be included to assess the safety and maximum tolerated dose-level of donor regulatory enriched T cell (Treg) in steroid-refractory chronic graft versus host disease (cGVHD) patients who did not obtain complete remission under treatment with ruxolitinib. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03683498
Study type Interventional
Source Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Contact
Status Completed
Phase Phase 1
Start date September 25, 2018
Completion date March 24, 2022

See also
  Status Clinical Trial Phase
Completed NCT01221766 - Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease N/A
Active, not recruiting NCT02067832 - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Active, not recruiting NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT05095649 - Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib Phase 2
Terminated NCT04852692 - A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants
Recruiting NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2